Nucleome Therapeutics

Executive Summary

Nucleome Therapeutics is a UK-based biotechnology company focused on precision medicines for inflammatory diseases. Founded in 2019 and headquartered in Oxford, the company leverages its proprietary 3D genomics platform to decode the non-coding 'dark genome,' linking disease-associated genetic variants to the genes they regulate. This approach enables the discovery of novel therapeutic targets and the development of genetically validated small molecules, antibodies, and biologics. By restoring immune homeostasis, Nucleome aims to address unmet needs in chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The platform's ability to interrogate the non-coding genome, previously underserved by conventional genomics, positions the company at the forefront of functional genomics-driven drug discovery. As a private, early-stage entity, Nucleome Therapeutics has not disclosed pipeline specifics, funding history, or valuation. However, its innovative platform and focus on genetically validated targets align with industry trends favoring precision medicine. The company's scientific founders and location in Oxford's thriving biotech cluster lend credibility. Near-term progress will depend on advancing platform validation, securing partnerships with larger pharma, and raising additional capital to support lead programs. While still preclinical, the technology's potential to unlock new druggable targets in inflammation offers significant upside if translationally successful.

Upcoming Catalysts (preview)

• 2026Series A or B Funding Round70% success
• 2026Major Pharma Partnership for Platform Access40% success
• TBDPreclinical Proof-of-Concept Data for Lead Program50% success